Table 3

Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype

Intent to treat analysis


KRAS wild-type

KRAS mutant

All


No

%

No

%

No

%


Enrolled patients

31

100

28

100

59

100

Evaluable patients

30

97

27

96

57

97

Objective response

27

90 (95% CI 79 to 100)

18

67 (95% CI 49 to 85)

45

79 (95% CI 68 to 100)

Partial response

23

77

17

63

40

70

Complete response

4

13

1

4

4

7

Stable disease

2

7

5

18.5

7

12

Progressive disease

1

3

4

15

5

9

Median PFS, months

14

11

12

Range

1+-69+

1+-60+

1+-69+

Progression events

25

81

20

71

45

76

Median OS, months

38

20

28

Range

1+-69+

1+-60+

1+-69+

Deaths

17

55

17

61

34

58

Liver metastasectomies

11

7

18

No/overall patients

11/31

35

7/28

25

18/59

31

No/patients with liver metastases

11/19

58

7/20

35

18/39

46

No/patients with L-L metastases

10/12

83

7/13

54

17/25

68

Pathologic complete responses

-

-

2

28.5

2

11


L-L = liver limited; OS = overall survival; PFS = progression-free survival.

Bruera et al. BMC Medicine 2012 10:135   doi:10.1186/1741-7015-10-135

Open Data